Atorvastatin and lovastatin, but not pravastatin, increased cellular complex formation between PCSK9 and the LDL receptor in human hepatocyte-like C3A cells-Reference-Cited by-同舟云学术

Atorvastatin and lovastatin, but not pravastatin, increased cellular complex formation between PCSK9 and the LDL receptor in human hepatocyte-like C3A cells

Published:2017-10 Issue:1 Volume:492 Page:103-108
ISSN:0006-291X
Container-title:Biochemical and Biophysical Research Communications
language:en
Short-container-title:Biochemical and Biophysical Research Communications

Author:

Melendez Quantil M.,Wooten Catherine J.,Lopez Dayami

Funder

State of North Carolina

BRITE

Atherotech Diagnostics Lab, Inc

Title III HBGI Integrated Biosciences Fellowship

Publisher

Elsevier BV

Subject

Cell Biology,Molecular Biology,Biochemistry,Biophysics

Reference35 articles.

1. Statin tolerability: in defence of placebo-controlled trials;Tobert;Eur. J. Prev. Cardiol.,2016

2. The success story of LDL cholesterol lowering;Pedersen;Circ. Res.,2016

3. An assessment by the statin intolerance panel: 2014 update;Guyton;J. Clin. Lipidol.,2014

4. Resistance and intolerance to statins;Reiner;Nutr. Metab. Cardiovasc Dis.,2014

5. Statin safety: a systematic review;Law;Am. J. Cardiol.,2006

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lipoprotein removal mechanisms and aging: implications for the cardiovascular health of the elderly;Current Opinion in Endocrinology, Diabetes & Obesity;2020-04

2. Erchen Decoction Ameliorates Lipid Metabolism by the Regulation of the Protein CAV-1 and the Receptors VLDLR, LDLR, ABCA1, and SRB1 in a High-Fat Diet Rat Model;Evidence-Based Complementary and Alternative Medicine;2018-10-08

3. Modulation of cardiovascular risk factors;Current Opinion in Lipidology;2018-06